BioSpace News Archive

Akoya Biosciences, Inc., The Spatial Biology Company®, announced the launch of PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery and validation on the PhenoImager® platforms.

23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the second quarter of its fiscal year 2023, which ended September 30, 2022.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2022.

ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical products, announced financial results for the quarter ended September 30, 2022.

Allakos Inc., a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, provided a business update and reported financial results for the third quarter ended September 30, 2022.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Candel Therapeutics, Inc. announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology in Tampa Bay, FL.

Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, has committed to make a new $449M investment in Certara.

Oyster Point Pharma, Inc., announced that it has entered into a definitive agreement under which Viatris Inc., a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced that it has been named the “2022 David J. Gury Company of the Year” by BioFlorida.